ZYME: FDA approval and a robust pipeline drive growth through innovation and royalty streams
FDA approval of zanidatamab in HER2-positive gastric cancer marks a new standard of care, with significant royalty and milestone potential. The pipeline includes next-gen T-cell engagers, ADCs, and innovative multispecific antibodies, supported by a hybrid royalty and R&D model and disciplined capi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.